Somewhere around 90% of the new chemical entities in development right now are poorly soluble. That number has quietly rewritten what the granulation step is for.
For most of the industry’s history, granulation existed to make powders behave. Better flow, less segregation, tablets that do not cap. Those goals have not gone away, but on a poorly soluble compound they are secondary. A tablet that looks perfect and dissolves at 5% in the gut is a failed product, and no amount of elegant compression changes that.
The flip side is that granulation is probably the most under-used tool we have for fixing solubility. Wet granulation, fluid bed layering, spray drying and hot melt extrusion can all be run as particle engineering rather than simple size enlargement. Below are the three mechanisms that actually move dissolution, followed by the failure modes that show up once those ideas reach a production floor.
Why poorly soluble drugs break conventional granulation
Conventional granulation quietly assumes the drug will dissolve once the tablet falls apart. Poorly soluble compounds break that assumption, usually for one of two reasons: the drug never gets wet, or the drug is pinned at its solubility ceiling no matter how much surface area you expose.
A standard immediate-release granulation buys you three things: flow, protection against segregation, and acceptable compaction. Not one of those has a necessary relationship with dissolution rate. You can hit every in-process target, compress beautiful tablets, and still deliver single-digit oral bioavailability because the molecule will not leave the solid state fast enough to cross a membrane.
So the framing has to change. With a poorly soluble compound, granulation is an interfacial and thermodynamic problem wearing a powder-handling costume.
The Noyes-Whitney anchor: two variables worth attacking
Every strategy below traces back to one equation. Noyes-Whitney says dissolution rate scales with the surface area of drug exposed to the dissolution medium and with its saturation solubility.
Two levers, then:
- Raise effective surface area. Smaller particles, better wetting, no agglomerates.
- Raise apparent saturation solubility. Amorphous form, solubilizing excipients, supersaturation.
The catch is that the two are not independent. Grind a drug down to nanoparticles and you gain surface area enormously. But if the powder is hydrophobic enough that water never reaches those particles, the surface area that matters at the moment of dissolution is roughly the outside of a handful of clumps. Each strategy below pulls one lever, and the formulations that survive scale-up tend to pull both.
Strategy 1: improve wettability through wet granulation
Wet granulation with a hydrophilic binder plus surfactant is the cheapest, most scalable way to improve dissolution of a hydrophobic drug. The mechanism is simple: trap the drug inside a hydrophilic matrix that pulls water inward the instant the tablet hits gastric fluid.
Plenty of poorly soluble drugs are also strongly hydrophobic. Blend one with excipients and compress it, and in aqueous media the drug particles clump. Water cannot get inside the agglomerate, so the effective surface area collapses to the outer shell of a few big clumps instead of the summed area of millions of separate particles.
Wet granulation fixes that by co-processing the hydrophobic API with hydrophilic polymers such as HPMC or HPC. The binder solution spreads over the drug surface, then solidifies, locking drug and polymer into one granule. In the GI tract the hydrophilic shell wets fast, wicks water into the granule interior, and the structure opens up from the inside out.
Two details decide whether you get that or not:
- The binder has to actually wet the drug. That is surface energy, governed by contact angle and the spreading coefficient. Negative spreading coefficient means the liquid beads up on the drug and ends up coating the excipients instead.
- The surfactant goes in the granulating liquid, never in the dry blend. That one is important enough to have its own section further down.
Strategy 2: nanoparticle granulation and matrix isolation
When micronization tops out, taking the drug to submicron or nanoparticle size (below 1 µm) raises total surface area exponentially. Nanoparticles cannot just be dried, though. They have to be locked into a carrier matrix during the drying step, or they agglomerate irreversibly and you lose the entire advantage you just paid for.
Two routes to drug nanoparticles:
- Top-down, meaning media milling, where a bead mill grinds coarse API into the nanometer range in a stabilizer solution.
- Bottom-up, meaning antisolvent precipitation, where the drug is dissolved and then crashed out as nanoparticles by mixing with an antisolvent.
Both give you a nanosuspension, and a nanosuspension is not an oral solid dosage form. Nanoparticles carry enormous surface free energy. Remove the liquid holding them apart and they fuse into rigid aggregates. This is the pattern I have seen more than once: brilliant dissolution from the suspension in R&D, then the dried and compressed tablet dissolves more slowly than plain micronized API. The size advantage was real. The drying step destroyed it.
Matrix isolation is the fix. Treat the nanosuspension as the spray liquid and apply it to a bed of soluble carrier. In fluid bed granulation you spray it onto mannitol or lactose starter cores; as the water evaporates, drug nanoparticles deposit on the carrier surface and in its pores, held apart from each other. Or you co-spray-dry the nanosuspension with a protective polymer such as PVP or HPMC, and each nanoparticle ends up wrapped in its own polymer shell.
Swallow that, and the carrier dissolves within seconds. The nanoparticles hit GI fluid at their original submicron size rather than as regrown aggregates, so the surface area you engineered in the mill is the surface area the gut actually sees.
Strategy 3: amorphous solid dispersions
Push size reduction to its logical end, molecular dispersion, and you get a solid dispersion. The crystal lattice is gone. The drug sits as an amorphous or molecularly dispersed phase inside a water-soluble polymer carrier, as a eutectic mixture, a glass solution, or a glass suspension.
Solid dispersions pull both Noyes-Whitney levers at once. Particle size is already molecular, so surface area stops being the constraint. More importantly, the amorphous form is a high-energy state with higher apparent solubility than the crystal, which generates a supersaturated solution in the gut.
That supersaturation is where the bioavailability comes from, and it is exactly what makes the approach risky. A supersaturated solution is thermodynamically desperate to crystallize, and it will take the first opportunity you give it.
Two processes dominate industrial production:
- Hot melt extrusion, which melts the polymer and disperses the drug under heat and shear, then cools the extrudate into a glass.
- Solvent evaporation, usually spray drying, which co-dissolves drug and polymer and strips the solvent in milliseconds.
Both run continuously or semi-continuously, which is a real advantage over batch granulation. Both also produce a material you have to protect from itself for the rest of its shelf life.
Three failure modes that appear during scale-up
Component segregation: the API stays in the fines
This is the classic wet granulation disaster with hydrophobic drugs. Run a high shear granulation with purified water and an extremely hydrophobic API, and the water droplets cannot spread on the drug, so they preferentially wet the hydrophilic excipients. Lactose and filler become large agglomerates. The API stays behind as ungranulated fine powder. Sieving then splits the batch into coarse granules carrying almost no drug and fines that are nearly pure drug. Content uniformity fails, and blending longer afterward will not reliably save it.
Worth naming the logic here, because it is what sends teams down the wrong path: this looks like a mixing failure and is actually a wetting failure. Blending is not the fix.
Nanoparticle drying agglomeration
Already covered, but it earns its own entry as a signature: dissolution from the nanosuspension is excellent, dissolution from the finished tablet is worse than micronized drug, and the loss traces to drying. If you see that shape, suspect irreversible agglomeration before you start reworking the formulation.
Physical aging and recrystallization of solid dispersions
An HME or spray-dried tablet can leave the plant with superb dissolution and then fall off a cliff after a few months on accelerated stability. XRD shows why. The amorphous drug recrystallized. Heat and absorbed moisture raise molecular mobility, molecules find each other, the lattice reassembles, and the high-energy state that gave you supersaturation is gone for good.
Control strategies that hold up in production
Put the surfactant in the granulating liquid
Do not dry-blend surfactant into the powder and then spray purified water. On a highly hydrophobic API that route fails, because the water still cannot spread on the drug fast enough for the surfactant to matter.
What works is dissolving a small amount of surfactant, polysorbate or sodium lauryl sulfate, straight into a low-viscosity binder solution, typically HPC. That drops the liquid-vapor surface tension so that a droplet hitting the powder bed achieves a positive spreading coefficient on the hydrophobic API immediately. Wetting becomes forced rather than optional, the drug gets pulled into the granule instead of left behind as fines, and the overwetted lumps that plague these batches mostly stop appearing.
Two interactions to watch while you tune this. Surfactant level and binder viscosity talk to each other: enough surfactant to wet the drug, not so much that you foam or stretch the drying time. And binder solution viscosity sets droplet size and penetration time into the bed, so switching binder grade changes wetting kinetics even at identical surfactant levels.
Build a thermodynamic safety margin for solid dispersions
For any amorphous solid dispersion, stopping moisture-induced recrystallization is job one. Before you lock the formulation, measure the glass transition temperature of the API-polymer mixture and build a Gordon-Taylor working curve showing how Tg falls as water content rises.
Then set one hard rule for manufacturing and packaging: product temperature stays at least 20 °C below the actual Tg at the product’s current moisture content. That single constraint forces three decisions you cannot dodge:
- Production needs low-humidity HVAC. A standard suite is not sufficient for a hygroscopic polymer carrier.
- Primary packaging needs a real moisture barrier, meaning cold-form aluminum foil rather than PVC blister.
- A desiccant belongs in the pack, because a barrier slows water ingress without stopping it.
Get those three right and you have effectively frozen molecular mobility for the shelf life of the product. Get them wrong and formulation elegance will not survive month six.
Choosing a route: a practical comparison
| Approach | Main lever | Typical process | Best when | Main risk |
| Wettability enhancement | Effective surface area | High shear or fluid bed wet granulation | Drug is hydrophobic but not at the extreme end of solubility limitation; cost pressure is real | Granulating liquid fails to wet the API; content uniformity drift |
| Nanoparticle matrix isolation | Surface area | Media milling or antisolvent precipitation, then fluid bed layering or spray drying | Micronization has plateaued; dose is moderate; drug is stable in suspension | Irreversible agglomeration during drying |
| Amorphous solid dispersion | Saturation solubility and supersaturation | Hot melt extrusion or spray drying | Solubility is the hard limit; drug survives HME heat or is soluble in a spray-drying solvent | Recrystallization on stability; moisture sensitivity |
Most programs work up that table from the bottom of the cost column. Wettability engineering is nearly always worth trying first because it runs on equipment you already own. If dissolution still misses, nanoparticle isolation is the next step up in complexity. Solid dispersions give the biggest gain and carry the heaviest development and stability burden, which makes them the right answer when the other two cannot reach the exposure target, not the default opening move.
Frequently asked questions
Why is granulation important for poorly soluble drugs? Granulation is the last step that can still change the drug’s interfacial and solid-state properties before compression. Beyond flow and compaction, it can embed hydrophobic drug in a hydrophilic matrix, hold nanoparticles apart inside a carrier, or create an amorphous dispersion. All three raise dissolution rate and oral bioavailability.
What is the Noyes-Whitney equation and why does it matter here? It relates dissolution rate to drug surface area and saturation solubility. Every solubility-enhancing granulation strategy works by raising one of those two, which makes it a quick sanity check on whether a proposed formulation change can plausibly help.
Why does my nanoparticle formulation dissolve more slowly after drying? Nanoparticles have very high surface free energy and agglomerate irreversibly once the liquid separating them is removed. Without carrier isolation during drying, either fluid bed layering onto mannitol or lactose, or co-spray-drying with PVP or HPMC, the dried powder loses the surface area advantage.
Should surfactant be dry-blended or dissolved in the binder solution? Dissolved in the binder solution. Dry blending surfactant and then spraying purified water leaves the wetting problem unsolved, since the water still cannot spread on a hydrophobic API. Dissolving polysorbate or SLS in a low-viscosity HPC binder solution drops surface tension enough to force wetting and pull the drug into the granule.
How do you stop an amorphous solid dispersion from recrystallizing? Keep the product at least 20 °C below its glass transition temperature at its actual moisture content. In practice: measure the Tg of the API-polymer system, build a Gordon-Taylor curve against water content, manufacture under low humidity, and pack in cold-form aluminum foil with a desiccant.
What causes API to concentrate in the fines during wet granulation? Poor wetting. When the granulating liquid cannot spread on a very hydrophobic API, it wets the hydrophilic excipients instead. Excipients granulate, the API stays as fines, and sieving produces a batch with unacceptable content uniformity.
The bottom line
Granulation for poorly soluble drugs has turned into a discipline of particle geometry and interfacial thermodynamics. Surfactant plus a hydrophilic matrix changes the interfacial energy between drug and water. Fluid bed layering or spray drying to isolate nanoparticles locks in a large effective surface area. Hot melt extrusion breaks the crystal lattice outright and buys solubility with stored energy you then have to defend for the life of the product.
None of these is universal. The choice comes down to whether your compound is limited by wetting, by surface area, or by saturation solubility, and how much stability risk the program can absorb. What does not work is treating solubility as somebody else’s problem, feeding a hydrophobic compound into a standard granulation process, and hoping the dissolution method is forgiving.

Comments are closed